Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06821191 · ClinicalTrials.gov registry record · Phase 4
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
A Phase 4 study of Coronary Artery Disease, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT06821191: Recruiting Phase 4 study of Coronary Artery Disease, sponsored by University of Florida.
NCT06821191 is a Phase 4 study of Coronary Artery Disease that is actively recruiting participants, run by University of Florida. The registered enrollment target is 78 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06821191, a Phase 4 study of Coronary Artery Disease, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant increase in bleeding events. Over time, different DAPT de-escalation strategies have been developed to reduce the bleeding risk while maintaining the ischemic protection, but there is currently no head-to-head comparison between them. The purpose of this clinical trial is to conduct a head-to-head comparison on the pharmacodynamic efficacy of DAPT de-escalation by dose reduction to low-dose prasugrel (5 mg od) and DAPT de-escation by switching from standard-dose more potent P2Y12 receptor inhibitor to standard-dose clopidogrel (75 mg). To determine if the PD profiles of these two strategies are comparable, we aim to conduct a non-inferiority study.
Primary Outcome
The primary endpoint of the study will be to establish non-inferiority by comparing PRU levels, determined using the VerifyNow system, between de-escalation through dose reduction to low-dose prasugrel (5 mg qd) and de-escalation through switching to standard-dose clopidogrel (75 mg qd) at trough levels.
Conditions Studied
Interventions
- DRUG clopidogrel 75 mg
- DRUG Prasugrel 5 mg
Study Locations (1)
Florida
- University of Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-01-07 |
| Phase | Phase 4 |
What NCT06821191 shows while recruiting
NCT06821191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which clopidogrel 75 mg is the first listed.
NCT06821191 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06821191 about?
NCT06821191 is a clinical study titled "Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study". Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant incr...
What is the current status of trial NCT06821191?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2025-03-10. Estimated completion is 2027-01-07.
What conditions does trial NCT06821191 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT06821191?
The interventions under investigation include: clopidogrel 75 mg (DRUG), Prasugrel 5 mg (DRUG).
Who is sponsoring clinical trial NCT06821191?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06821191 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06821191's enrollment target sits among peer trials
78 160th of 219 higher than 60 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
RECRUITING · Phase 4
-
The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial
RECRUITING · Phase 4
-
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
RECRUITING · Phase 4
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
RECRUITING · Phase 4
-
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
RECRUITING · Phase 4
-
Etomidate Versus Propofol in CABG Surgery
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI